Figma Inc. Class A Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.23 (market cap $11.60B), while NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B). The key difference: Figma Inc. Class A Common Stock is far larger — about 5.4× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| FIG | NEO | |
|---|---|---|
Market Cap | $11.60B | $2.14B |
Volume | 12,281,013 | 2,228,400 |
Sector | Technology | Health |
52-Week High | $63.82 | $19.91 |
52-Week Low | $16.84 | $7.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.00B | $2.44B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →